Canaccord Genuity Slashes PT on Enovis Corporation (ENOV) to $50 From $58

Core Insights - Enovis Corporation (NYSE:ENOV) is identified as a promising small-cap stock with significant upside potential, despite recent adjustments to price targets by analysts [1][2] - The company is experiencing a rebound in organic growth, particularly in 2025, with expectations for continued momentum [2][3] - Enovis reported a 9% increase in net sales for fiscal Q3 2025, reaching $549 million, driven by stable end markets and successful new product introductions [4] Analyst Ratings and Price Targets - Canaccord Genuity reduced its price target for Enovis to $50 from $58 while maintaining a Buy rating, reflecting updated 2027 estimates [1] - Freedom Capital initiated coverage with a Buy rating and set a price target of $45, highlighting the company's improving competitive positioning [2][3] Financial Performance - In fiscal Q3 2025, Enovis's net sales rose 9% on a reported basis and 7% on an organic basis compared to the previous year [4] - The Reconstructive segment saw a 2% increase in reported sales and a 9% increase in organic sales, while the Prevention & Recovery segment grew 6% on a reported basis and 4% organically [4] Company Overview - Enovis Corporation is a medical technology growth company focused on developing clinically differentiated solutions aimed at improving workflows and patient outcomes [5]